JPRN-jRCT1080224720Completed未知
TR research associated with 'A multicenter Phase II basket-type clinical trial to evaluate efficacy and safety of TAS-120 in patients with advanced solid malignancies with FGFR alterations in circulating tumor DNA (TiFFANY study)'
ational Cancer Center Hospital East0 sites26 target enrollmentStarted: June 10, 2019Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 26
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 20age old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- •Patients enrolled in treatment group in 'A multicenter Phase II basket-type clinical trial to evaluate efficacy and safety of TAS-120 in patients with advanced solid malignancies with FGFR alterations in circulating tumor DNA(TiFFANY study)'
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Completed
Not Applicable
TR study of "A multicenter phase II study of eribulin monotherapy in patients with BRAF V600E mutant metastatic colorectal cancer (BRAVERY study)"BRAF V600E mutant metastatic colorectal cancerJPRN-UMIN000031552Aichi Cancer Center Hospital27
Completed
Not Applicable
Safety and Immunogenicity Study of the New dHER2 Vaccine to Treat HER2-positive Metastatic Breast Cancer-C509 Breast, unspecifiedBreast, unspecifiedC509PER-009-06GLAXOSMITHKLINE BIOLOGICALS,
Completed
Not Applicable
TR study of "multicenter Phase II study to evaluate efficacy and safety of combination therapy with trastuzumab and pertuzumab in patients with HER2-positive metastatic colorectal cancer"colorectal cancerJPRN-UMIN000030505ational Cancer Center Hospital East30
Recruiting
Phase 1
A phase Ib/II, multicenter study to investigate the safety, efficacy, and proof-of-concept (POC) of nivolumab monotherapy as a sequential therapy following preoperative chemoradiotherapy in patients with locally advanced resectable rectal cancerRectal cancerJPRN-UMIN000023148ational Cancer CenterHospital East50
Completed
Phase 1
Phase Ia/Ib multicenter investigator initiated trial of Mogamulizumab for advanced or recurrent cancer.Advanced or recurrent cancerJPRN-UMIN000010050Aichi Medical University School of Medicine, Department of Tumor Immunology58